– Reliable and accurate control will provide unequivocal effects in 1 minute, for immediate antigen controls (30 minutes)
– Designed for use in schools, events, companies, hotels or airports, where diagnosis is important.
– Reliable and easy to use, for the qualitative detection of SARS-CoV-2 express antigens provided in human, nasal or nasopharyngeal saliva
– Immediately identify contagious Americans inflamed by SARS-CoV-2
– A COVID-19 antibody panel is being developed at the care site (5 minutes before results) to identify immunized patients and consulting physicians on vaccination strategy.
LAUSANNE, Switzerland, Nov. 30, 2021 /PRNewswire/ — Abionic SA, a developer of disruptive diagnostic solutions based on nanotechnology, has announced the CE (European Conformity) marking of a new one-minute COVID-19 saliva control employing its cutting-generation testing platform, abioSCOPE. This step allows Abionic to commercialize its ultra-fast verification of the identity of Americans inflamed by SARS-CoV-2 in the European Union. Designed for use in schools, events, businesses, hotels or airports, where rapid diagnosis is critical, the check can spell a renaissance for the beleased hospitality sector that has lost millions of euros while bars, hotels and restaurants have paid the price for pandemic restrictions. Similarly, it can allow schools to remain open, offering continuity in education, and allow airports to speed up passenger pleasure and inspire travelers to fly again.
Clinical knowledge of IVD CAPSULE COVID-19 ultrafast antigen control is based on studies involving 119 Americans and has demonstrated far superior sensitivity to identifying infectious Americans with a lot of virus measured via Ct PCR
The use of the formula is simple: after collecting the saliva, the user mixes it with the reagent to reveal the nucleoprotein. The aggregate is distributed to the IVD CAPSULE which is loaded into the tray of the abioSCOPE reading device. After about 1 minute, the result is received directly on the abioSCOPE screen. The result is unequivocal and can be automatically transferred via a secure knowledge transmission protocol that employs the abioSCOPE’s built-in Ethernet port.
Abionic’s 1-minute QUANTIFICATION of the COVID-19 saliva antigen also provides data on possible patient contagion, allowing for rapid preventive decision-making: “Does the patient constitute a threat of disease spread?”It is designed to be used in schools, events, companies, hotels or airports, where rapid decision-making about the prestige of COVID is critical.
Abionic will also present a nasal/nasopharyngeal edition of the IVD CAPSULE: In situ COVID-19 antigen diagnostic tests will allow healthcare professionals to factor in an official COVID passport or COVID pass extension. offices or pharmacies, where immediate effects are important. The company is lately preparing for inclusion on the EU Common List.
“We are pleased to offer the right equipment to create certain COVID-free environments,” said Dr. Nicolas Durand, CEO of Abionic. “Getting a result in 1 minute reopens the doors of sell options that were once closed to many people Getting CE marked for our CAPSULE Saliva COVID-19 IVD is a vital step in offering access to ultra-fast, high-precision testing in the European Union and beyond. We are proud to be an active component of the global effort to get back to normal. “
The IMD business school is lately experimenting with saliva testing at its Lausanne campus. Louis Leclézio, CDO IMD, commented: “We have a foreign profile of mobile executive participants and a network of students. It is a priority for us to make sure that our participants arrive and leave in complete health. It is vital for us to continue to ensure that an environment is informed without disrupting its ability to be informed at IMD. To manage this constantly changing process, we are now testing Abionic’s solution as we need do you have the ability to temporarily assess the Covid prestige of those on our campus?and make decisions accordingly. “
Large-scale COVID-19 serology
The COVID-19 pandemic will intensify again, despite an encouraging decline in cases in the spring and summer of 2021, due to the successful rollout of vaccination. may pose a risk to public health. Therefore, many countries are contemplating the advent of antibody tests for COVID-19, which are tests to determine if a user has accumulated antibodies against the virus, which can protect them from reinfection. and allow them to paint and without restrictions.
Abionic announces the progression of an immediate serological control (5 minutes), (from a drop of capillary blood) and quantitative (determination of antibody levels) that quantifies the IgG proteins of the nucleus and the peak.
This quantitative serology panel is expected to have CE marking at the time of the quarter of 2022, when existing studies have determined the point of the antibodies needed for immunity. An immediate control with capillary blood simplifies the patient’s adventure and allows for a single appointment/step. In addition, this control, which will be used in the abioSCOPE platform, will allow the personalization of vaccination and not vaccination in the population. burden on the health system.
“The main merit of Abionic’s solution is that it can perform a serology directly in a matter of minutes, unlike laboratory tests that take more than 24 hours to discharge the effects and require an immediate appointment,” said Dr. Alessandro Diana, medical director. from the Qorpus Hirlsanden Medical Center in Geneva, and an expert vaccinologist at Infovac. “This simplification is, in our view, the key to facilitating and offloading herd immunity more temporarily and making sure the population adheres to vaccination. “
About Abionic
Founded in 2010, Abionic is a Swiss medical generation company that markets the revolutionary generation of nanofluids in more than 25 countries, providing healthcare professionals with a fast, undeniable and universal diagnostic tool. characteristics of the care remedy (POC) with the ability to reduce existing biological techniques from the macroscale to the nanoscale in a multi-analyte environment.
Abionic’s in vitro diagnostic (IVD) platform provides ultrafast laboratory-grade effects from an unwred drop of the patient’s pattern (saliva, blood, urine, etc. ) to the POC, allowing for personalized diagnostics and the option of immediate treatment. basically active in acute care (early identification of sepsis, severity of COVID-19) and in number one care (allergy, iron deficiency).
For more information, https://www. abionic. com/.
Logo: https://mma. prnewswire. com/media/1696496/Abionic_Logo. jpg Photo – https://mma. prnewswire. com/media/1696689/Abionic_COVID_19_Saliva_Test. jpg
Contacts